Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04536857
Recruitment Status : Not yet recruiting
First Posted : September 3, 2020
Last Update Posted : September 3, 2020
Sponsor:
Information provided by (Responsible Party):
Jian Wang, Huashan Hospital

Brief Summary:
The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease duration less than 1 year, compared with that from age-matched controls without neurodegeneration, those with Multiple System Atrophy (MSA) as a disease control with a-synucleinopathy, and those with Progressive Supranuclear Palsy (PSP) as a control with non-a-synucleinopathy neurodegeneration.

Condition or disease Intervention/treatment
Parkinson's Disease Other: Biomarker assay

Detailed Description:

This will be an observational study aiming to develop the protein misfolding cyclic amplification (PMCA) technology that detects minute amounts of αSyn aggregates circulating in cerebrospinal fluid (CSF) as a novel assay with high sensitivity and specificity for the early diagnosis of PD. To achieve this goal, we will apply the PMCA to detect the αSyn aggregates in the CSF samples acquired from a discovery cohort that consist of well-characterized early PD patients (disease duration ≤1 year and Hoehn and Yahr Stage I, and DAT-PET and FDG-PET meet the imaging features of PD, n=75) and gender, age-matched healthy controls (n=38). Furthermore, we will confirm the findings in a separate confirmatory cohort with well-characterized early PD patients (disease duration ≤1 year and Hoehn and Yahr Stage I, and DAT-PET and FDG-PET meet the imaging features of PD, n=75), early multiple system atrophy (MSA) patients (disease duration ≤1 year, n=38), early progressive supranuclear palsy (PSP) patients (disease duration ≤1 year, n=38) and age-matched healthy controls (n=38). The sensitivity, specificity, positive predictive value, negative predictive value, and area under curve of the PMCA for the early diagnosis of PD will be calculated in the discovery cohort and be confirmed in the confirmatory cohort, respectively. In addition, the clinical characteristics, including motor and nonmotor symptoms of early PD, MSA and PSP patients in the two cohort will be comprehensively assessed at baseline and during followed-up. To assess the value of the PMCA technology in the evaluation of the disease severity and progress, we will perform the partial correlation analysis between clinical features of early PD patients and the PMCA T50 defined as the time needed to reach 50% of the maximum aggregation.

Misfolded αSyn aggregates have the potential to serve as a biomarker for early PD. The PMCA technology could detect small quantities of misfolded αSyn aggregates by taking advantage of their ability to nucleate further aggregation, enabling a very high amplification of the signal. This study examines the effectiveness of using the PMCA as a novel technique for discriminating early PD from gender, age-matched healthy controls and other early parkinsonian disorders (MSA, PSP) by detecting small misfolded αSyn aggregates in CSF.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 302 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : September 30, 2022

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Parkinson's Disease
Subjects who have a PD diagnosis
Other: Biomarker assay
Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.

Multiple System Atrophy
Subjects who have an MSA diagnosis
Other: Biomarker assay
Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.

Progressive Superanuclear Palsy
Subjects who have a PSP diagnosis
Other: Biomarker assay
Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.

Age-matched controls
Subjects who do not have a diagnosed neurological disorder
Other: Biomarker assay
Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.




Primary Outcome Measures :
  1. The area under curve of the PMCA for the early diagnosis of PD [ Time Frame: two years ]
    The area under curve is used to show the ability of the a-syn-PMCA to diagnose early PD. The value of area under curve is higher, then the ability of the a-syn-PMCA to diagnose early PD is stronger.


Secondary Outcome Measures :
  1. The correlation between the PMCA T50 and MDS-UPDRS III score at baseline in PD patients [ Time Frame: two years ]
    PMCA T50 is the time needed to reach 50% of the maximum aggregation. The motor symptoms of PD patients will be assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS- III).

  2. The correlation between PMCA T50 and subregional DAT in striatum in PD patients [ Time Frame: two years ]
    PMCA T50 is the time needed to reach 50% of the maximum aggregation. The DAT uptake value (caudate, anterior putamen and/or posterior putamen) will be quantified using DAT-PET.

  3. The correlation between PMCA T50 and PDRP expression value in PD patients [ Time Frame: two years ]
    PMCA T50 is the time needed to reach 50% of the maximum aggregation. The Parkinson's disease-related pattern (PDRP) expression value will be quantified by using FDG-PET.

  4. The correlation between PMCA T50 and the change of MDS-UPDRS III score between the baseline and the follow-up [ Time Frame: two years ]
    PMCA T50 is the time needed to reach 50% of the maximum aggregation. The change of MDS-UPDRS III score is the difference of that between the baseline and the follow-up.

  5. The sensitivity [ Time Frame: two years ]
    The sensitivity is used to show the ability of the a-syn-PMCA to diagnose early PD patients, and is represented by true positive/ (true positive +false negative).

  6. The specificity [ Time Frame: two years ]
    The specificity is used to show the ability of the a-syn-PMCA to avoid false early PD patients and rule out early PD patients, and is represented by true negative/ (false positive + true negative).

  7. The positive predictive value [ Time Frame: two years ]
    The positive predictive value is used to show the ability of the a-syn-PMCA to correctly label early PD patients who test positive, and is represented by true positive / (true positive + false positive).

  8. The negative predictive value [ Time Frame: two years ]
    The negative predictive value is used to show the ability of the a-syn-PMCA to correctly label people who test negative, and is represented by true negative / (false negative + true negative).


Biospecimen Retention:   Samples Without DNA
cerebrospinal fluid


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Discovery cohort: (1) Early PD patients (disease duration ≤1 year and Hoehn and Yahr Stage I, n=75); (2) Gender, age-matched healthy controls (n=38); (3) The dopamine reuptake transporter (DAT) is significantly reduced in striatum on PET imaging; (4) Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with Parkinson's disease-related pattern (PDRP).

Confirmatory cohort: (1) Early PD patients (disease duration ≤1 year and Hoehn and Yahr Stage I, n=75); (2) Early Multiple System Atrophy (MSA) patients (disease duration ≤1 year, n=38); (3) Early progressive supranuclear palsy (PSP) patients (disease duration ≤1 year, n=38); (4) Gender, age-matched healthy controls (n=38); (5) The dopamine reuptake transporter (DAT) is significantly reduced in striatum on PET imaging; (6) Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with Parkinson's disease-related pattern (PDRP).

Criteria

For early PD patients

Inclusion criteria:

  • Clinical diagnosis of "probable PD" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD (2015);
  • Age 50-75, disease duration is less than 1 year, and Hoehn & Yahr Stage I;
  • the dopamine reuptake transporter (DAT) is significantly reduced in striatum on PET imaging;
  • Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with Parkinson's disease-related pattern (PDRP), with FDG hypermetabolism being in basal ganglia and cerebellum;
  • Good response to anti-PD medications;
  • Ability of completing questionnaires;
  • Ability of providing informed consent;
  • Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment.

Exclusion criteria:

  • Secondary parkinsonism (ie. drug induced);
  • Atypical parkinsonisms like MSA or PSP etc;
  • Presence of any item in 10 red flags of the MDS Clinical Diagnostic Criteria for PD (2015) in the comprehensive assessments during follow-up;
  • History of being diagnosed as any cancer within 5 years;
  • Presence of any condition risking the procedure of performing lumbar puncture (LP);
  • Pregnancy;
  • Inability to comply with study procedures.

For early MSA patients

Inclusion criteria:

  • Clinical diagnosis of "probable MSA" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) second consensus criteria for MSA (2019);
  • Age 50-75, and disease duration is less than 1 year;
  • Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with MSA related pattern;
  • Ability of completing questionnaires;
  • Ability of providing informed consent;
  • Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment.

Exclusion criteria:

  • Secondary parkinsonism (ie. drug induced);
  • History of being diagnosed as any cancer within 5 years;
  • Presence of any condition risking the procedure of performing lumbar puncture (LP);
  • Pregnancy;
  • Inability to comply with study procedures.

For PSP patients

Inclusion criteria:

  • Clinical diagnosis of "probable PSP" by two neurologists specializing in movement disorders according to MDS Clinical Diagnostic Criteria for PSP (2017);
  • Age 50-75, disease duration is less than 1 year;
  • Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with PSP related pattern;
  • Ability of completing questionnaires;
  • Ability of providing informed consent;
  • Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment.

Exclusion criteria:

  • Secondary parkinsonism (ie. drug induced);
  • History of being diagnosed as any cancer within 5 years;
  • Presence of any condition risking the procedure of performing lumbar puncture (LP);
  • Pregnancy;
  • Inability to comply with study procedures.

For controls without diagnosis of neurodegenerative disorders

Inclusion criteria:

  • Age 50-75;
  • No history of neurodegenerative disease of the central nervous system;
  • No history of infective disease of the central system;
  • Ability of completing questionnaires;
  • Ability of providing informed consent.

Exclusion criteria:

  • With prodromal symptoms of PD, such as rapid eye movement sleep behavior disorder (RBD);
  • History of being diagnosed as any cancer within 5 years;
  • Presence of any condition increasing the risk of the procedure of performing lumbar puncture (LP);
  • Pregnancy;
  • Inability to comply with study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04536857


Contacts
Layout table for location contacts
Contact: Jian Wang, MD 86-21-52888160 wangjian336@hotmail.com, Wangjian_hs@fudan.edu.cn
Contact: cuiyun wu, master 86-21-52888047 wucuiyun@fudan.edu.cn

Sponsors and Collaborators
Huashan Hospital
Investigators
Layout table for investigator information
Principal Investigator: Jian Wang, MD Huashan Hospital
Layout table for additonal information
Responsible Party: Jian Wang, Professor & Deputy Director, Department of Neurology, Huashan Hospital
ClinicalTrials.gov Identifier: NCT04536857    
Other Study ID Numbers: 2020 Provisional Audit No.1004
First Posted: September 3, 2020    Key Record Dates
Last Update Posted: September 3, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jian Wang, Huashan Hospital:
Parkinson's disease (PD)
αSyn aggregates
Protein misfolding cyclic amplification (PMCA)
Early diagnosis
CSF
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases